Skip to content

ICAAC: Phase 1 study provides `proof of concept` for PRO 140, a monoclonal CCR5 antibody

ICAAC: No drug interactions found between TMC125 and ritonavir-boosted elvitegravir

ICAAC: Maraviroc failures associated with shifts from R5-tropic to mixed or X4-tropic HIV

ICAAC: Incidence of non-AIDS-defining cancers remains higher for HIV-positive individuals despite HAART

ICAAC: Sharp decline in HIV prevalence reported in pregnant women in rural northern Zimbabwe

ICAAC: Dapivirine safe and tolerable as potential vaginal microbicide; displays potential in combination with other agents

ICAAC: 48-week results show maraviroc still potent in highly treatment-experienced

ICAAC: Gardasil provides some protection against wide spectrum of cancer-causing HPV

ICAAC: Dual/mixed tropic virus speeds disease progression as much as tenfold increase in viral load